

# Drug Discovery 2016

ACC, LIVERPOOL

13th - 14th October 2016



#ELRIGDD16

## Oncology & Immunology

THURSDAY 13<sup>TH</sup> OCTOBER: HALL 1B

Towards the end of the 19th century, evidence had emerged pointing to the role of the immune system in combating cancers. Coleys toxin carried the tentative promise of long term anti-tumor responses through stimulating the immune system. During the 20th century, key advances were made in the discovery and characterisation of cellular and molecular players involved in immune recognition of cancer cells. These discoveries led to the recent wave of immunotherapeutic agents, T cell checkpoint blockers, with demonstrable durable anti-tumor activity, initially in melanoma, and expanding to other indications. There are now a plethora of immunotherapeutic modalities in clinical development; these are being tested as single agents and in combination. This track will review the various modalities showing promise, including protein based biologics and cell therapies, as well as surveying the tumor landscape for opportunities to disrupt the tumor micro environment.

**CHAIRS: Namir Hassan, Immunocore and David Gilham, Manchester Cancer Research Centre**

TIME	SPEAKER	TITLE
8:45 - 9:30	<b>PLENARY KEYNOTE: ROOM 3</b> <b>Professor Chas Bountra</b> Oxford SGC - University of Oxford	TBA
9:30 - 9:45	<b>Session Chairs</b>	<b>Introduction and Welcome</b>
9:45 - 10:30	<b>Robert Wilkinson</b> Medimmune	<b>Immuno-oncology: harnessing the immune system to combat cancer</b>
10:30 - 11:00	<b>David Krige</b> ImmunoCore	<b>Biomarker Strategy to Guide Clinical Development of ImmTAC's, a Novel Class of Biologic Drugs Based on Proprietary T cell receptor (TCR) Technology</b>
11:00 - 11:30	<b>COFFEE BREAK</b>	
11:30 - 12:00	<b>Martin Pule</b> UCL	TBA
12:00 - 12:30	<b>POSTER TASTERS</b>	
12:30 - 13:00	<b>SNAPSHOT PRESENTATIONS</b> - Essen Bioscience Ltd, Promega UK Ltd, IntelliCyt Corporation, Tecan	
13:00 - 14:30	<b>LUNCH - EXHIBITION - POSTERS</b>	
14:30 - 15:15	<b>PLENARY KEYNOTE: ROOM 3</b> <b>Professor Munir Pirmohamed</b> David Weatherall Chair in Medicine, Royal Liverpool University Hospital	<b>Drug Safety in Drug Development</b>
15:15 - 15:45	<b>Caroline Dive</b> Manchester University	<b>New Patient Relevant Models to Evaluate Much Needed Therapeutics for Small Cell Lung Cancer</b>
15:45 - 16:15	<b>Claus Jorgensen</b> Cancer Research UK Manchester Institute	<b>Analysis of Reciprocal Tumour-Stroma Signalling by Cell-Specific Phosphoproteomics</b>
16:15 - 16:45	<b>Thierry Wurch</b> Servier	<b>Immunotherapy in the 21st Century: A Game Changing Paradigm in Oncology</b>
16:45 - 17:45	<b>POSTER SESSION</b>	
17:00 - 19:00	<b>DRAGON'S DEN/NETWORKING/DRINKS RECEPTION</b>	

[www.elrig.org/drug-discovery-2016](http://www.elrig.org/drug-discovery-2016)